Abstract Library

#4666 Merkel cell neuroendocrine carcinoma of the skin: High response rates to short course palliative radiotherapy – Typical clinical scenarios

Introduction: Merkel cell carcinomas (MCC) are a rare, aggressive skin neuroendocrine carcinomas, with peak incidence in the elderly. MCC often presents as a firm, red/purple painless nodule with a short history of increasing size. Surgery is considered the 1st line treatment but elderly patients, in particular, have comorbidities which may preclude radical surgery requiring reconstruction. In advanced MCC, immunotherapy (IO) is 1st line systemic treatment. Chemotherapy is used 2nd line or if contraindications for IO but can be challenging in an elderly population. There may be an emerging role for PRRT due to the presence of somatostatin receptors on MCC. Radiotherapy (RT) can be used for non-surgical candidates, or those with unresectable or metastatic disease. Adjuvant post-operative irradiation (PORT) may provide additional benefit in risk reduction and improves local control.

Conference:

Presenting Author:

Authors: Saunders E, Sizer B, Collins J, Skelly R, Srinivasan G,

Keywords: Merkel cell, skin, radiotherapy,

#4663 CAREFNDR: A phase III, randomised, parallel group, placebo-controlled study to evaluate the efficacy and safety of paltusotine in adults with carcinoid syndrome due to well-differentiated neuroendocrine tumours

Introduction: Paltusotine is a once-daily, oral, nonpeptide, selective SST2 receptor agonist in development for carcinoid syndrome (CS) treatment. In a Phase 2, open-label, dose-ranging study, paltusotine reduced the frequency and severity of CS symptoms and was well tolerated (NCT05361668).

Conference:

Presenting Author:

Authors: Kim R, Usiskin K, Fan X, Quock T, Mui C,

Keywords: paltusotine, phase 3 trial, somatostatin receptor agonist, neuroendocrine tumour, carcinoid syndrome,

#4601 Pembrolizumab combined with cisplatin or carboplatin and etoposide in treatment naïve advanced Merkel cell carcinoma (MCC): The phase II PANDORA Trial

Introduction: MCC is a rare and aggressive skin neuroendocrine tumour with high metastatic potential and mortality. Therapeutic options in metastatic/unresectable MCC are based on immunotherapy or platinum-based chemotherapy. However, a subgroup of patients (pts) has primary immunoresistance disease, so it would be important discover active upfront combinations. PANDORA trial [NCT 06086288] is an open-label, multicentre, single-arm phase II trial evaluating the activity and safety of pembrolizumab (PEM) combined with platinum-based chemotherapy as 1st line treatment in pts with metastatic, unresectable or recurrence MCC. Supported in part by a research grant from Investigator-Initiated Studies Program of MSD.

Conference:

Presenting Author: Oldani S

Authors: Oldani S, Morano F, Cingarlini S, Di Giacomo A, Borghesani M,

Keywords: Pembrolizumab, clinical trial, Merkel cell carcinoma, chemio-immunotherapy,

#4575 Once-daily oral paltusotine in the treatment of patients with carcinoid syndrome: Safety and exploratory efficacy results from a phase II, randomised, parallel-group study

Introduction: Paltusotine is a once-daily, oral, nonpeptide, selective SST2 receptor agonist in development for the treatment of carcinoid syndrome (CS).

Conference:

Presenting Author: Hajac L

Authors: Hajac L, Chauhan A, Mohamed A, Usiskin K, Mui C,

Keywords: paltusotine, phase 2 trial, somatostatin receptor agonist, safety, carcinoid syndrome,

#4500 Effectiveness of palbociclib plus letrozole as first line therapy of metastatic breast neuroendocrine carcinoma: A case report

Introduction: Palbociclib plus endocrine therapy is the standard treatment of advanced luminal breast cancer. However, we lack data on its effectiveness in breast neuroendocrine carcinoma (NEC).

Conference:

Presenting Author:

Authors: Saidi M, Aris H, Elyebdri H, Ilham L,

Keywords: breast neuroendocrine carcinoma, CDK4/6 inhibitor, palbociclib, endocrine therapy,